March 16, 2021 -- Moderna announced that the first participants have been dosed in its phase II/III study of its pediatric messenger RNA (mRNA) COVID-19 vaccine candidate, mRNA-1273.
The study, called KidCove, will eventually include 6,750 healthy children between six months and 12 years of age from the U.S. and Canada. It is being conducted in partnership with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA), and will evaluate the safety, tolerability, reactogenicity, and effectiveness of two doses of the vaccine administered 28 days apart.
Moderna also announced that it has begun dosing the first participants in a phase I study evaluating its next generation COVID-19 vaccine, mRNA-1283, a refrigerator-stable mRNA drug that the company hopes will allow for easier distribution and administration, it said.
Copyright © 2021 scienceboard.net